F
12.99
4.09 (45.96%)
| Previous Close | 8.90 |
| Open | 12.85 |
| Volume | 24,674,474 |
| Avg. Volume (3M) | 670,068 |
| Market Cap | 702,998,528 |
| Price / Sales | 2.66 |
| Price / Book | 2.43 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -0.64% |
| Operating Margin (TTM) | -13.00% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 3.55% |
| Current Ratio (MRQ) | 28.71 |
| Operating Cash Flow (TTM) | 7.81 M |
| Levered Free Cash Flow (TTM) | 4.40 M |
| Return on Assets (TTM) | -2.74% |
| Return on Equity (TTM) | -0.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Fulcrum Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | -0.75 |
|
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 96.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2025 | 5,381,000 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 5,250,000 |
| Nantahala Capital Management, Llc | 30 Sep 2025 | 4,670,784 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (HC Wainwright & Co., 92.46%) | Buy |
| Median | 23.00 (77.06%) | |
| Low | 10.00 (RBC Capital, -23.02%) | Hold |
| Average | 19.20 (47.81%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 12.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 08 Dec 2025 | 24.00 (84.76%) | Buy | 12.99 |
| HC Wainwright & Co. | 08 Dec 2025 | 25.00 (92.46%) | Buy | 12.99 |
| 24 Nov 2025 | 18.00 (38.57%) | Buy | 11.74 | |
| Piper Sandler | 08 Dec 2025 | 23.00 (77.06%) | Buy | 12.99 |
| 30 Oct 2025 | 16.00 (23.17%) | Buy | 8.60 | |
| RBC Capital | 08 Dec 2025 | 10.00 (-23.02%) | Hold | 12.99 |
| 30 Oct 2025 | 7.00 (-46.11%) | Hold | 8.60 | |
| Truist Securities | 24 Nov 2025 | 14.00 (7.78%) | Buy | 11.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |